Transdermal progesterone or synthetic progestogens

Journal of the British Menopause Society

Volumn 7, Issue 3, 2001, Pages 115-118

  Wren, Barry G ^a,b  

^a Sydney Menopause Centre   (Australia)

^b ROYAL HOSPITAL FOR WOMEN   (Australia)

Author keywords

Cardiovascular disease; Endometrium; Osteoporosis; Progesterone; Progestogens

Indexed keywords

ESTRADIOL; ESTROGEN; GESTAGEN; LEVONORGESTREL; NORETHISTERONE; NORETHISTERONE ACETATE; PLACEBO; PROGESTERONE; TRIMEGESTONE;

BREAKTHROUGH BLEEDING; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CLINICAL TRIAL; CREAM; DEGRADATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG USE; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; FEMALE; GEL; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; MITOSIS INHIBITION; OSTEOPENIA; OSTEOPOROSIS; PROTECTION; REVIEW; SIDE EFFECT; TRANSDERMAL PATCH;

EID: 0034805159     PISSN: 13621807     EISSN: None     Source Type: Journal    
DOI: 10.1258/136218001100321399     Document Type: Review

References (30)

1. Risk of endometrial cancer following estrogen replacement with and without progestins
2. Osteoporosis reversal: The role of progesterone
3. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen
4. A study to evaluate serum and urinary hormone levels following short and long term administration of two regimens of progesterone cream in postmenopausal women
5. Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women
6. Micronised transdermal progesterone and endometrial response
7. "Natural" progesterone creams for postmenopausal women
8. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo
9. Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women
10. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss
11. Transdermal delivery of estradiol and levonorgestrel
12. Hormone replacement therapy preparations
13. Physical evaluation of a new patch made of a progestomimetic in a silicone matrix
14. Development of a combined norethisterone acetate/estradiol TTS
15. Endometrial effects of transdermal estradiol/norethisterone acetate
16. A randomised comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause
17. Consensus on preventing osteoporosis
18. Long term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss
19. Effects of combined sequential transdermal estradiol and norethindrone acetate HRT on bone markers in postmenopausal women
20. One year double-blind, randomized trial of continuous transdermal estradiol and norethindrone acetate vs. estradiol transdermal HRT on bone markers
21. A randomised comparison of the effects of oral versus transdermal 17β oestradiol, each combined with sequential oral norethisterone acetate, on serum lipoprotein levels
22. Comparison of continuous & sequential oral progesterone in postmenopausal women using continuous transdermal oestrogen: Vasomotor symptoms, bleeding pattern and serum lipids
23. Long-term effects of oral and transdermal hormone replacement therapies on lipid and lipoprotein concentrations
24. Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy
25. Hormone replacement therapy is associated with improved endothelium dependent dilatation in healthy postmenopausal women
26. The long-term effects of oral and transdermal postmenopausal hormone replacement therapy on nitric oxide, endothelin-1, prostacyclin and thromboxane
27. The effect of sequential estrogen/progestin treatment on biochemical vasoactive markers in postmenopausal women containing oral and transdermal application
28. Administration of transdermal estrogen without progestin increases the capacity of plasma and serum to stimulate prostacyclin production in human vascular endothelial cells
29. Effects of oral and transdermal 17 beta estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion and elimination in post menopausal women
30. Comparative pharmacology of newer progestogens